TrialThe Journal of urology2024

Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial.

Vikram M Narayan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.